Prevention of Diabetes Progression Trial (PDPT)

Completed · Phase 2

Conditions studied: Newly Diagnosed With Type 1 Diabetes

In brief

The primary purpose of this study is to determine the efficacy and safety of daclizumab in preventing the progression of diabetes in children who have just been diagnosed with type I diabetes. Additional purposes of the study are to investigate the amount of drug in the children, how quickly it is eliminated from the blood, and analyze the effect of the drug on the immune reaction to diabetes.

Key facts

Study ID

NCT00198146

Run by

Indiana University

People needed

40

Starts

2000-07-01

Expected to finish

2007-02-23

Last updated by the study team

2020-08-11

Who can join

Age: 2 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed type 1 diabetes without previous insulin or oral hypoglycemic therapy.
• ages 2 to 40 years at diagnosis
• enroll within 3 months of diagnosis
• test positive for at least one of the biochemical autoantibodies (ICA-512, GAD 65 or IAA) prior to enrolling

You may not qualify if…

• Previous treatment with an anti-IL-2 directed monoclonal antibody or any other investigational agent that would interfere with the ability to evaluate the safety and efficacy of daclizumab.
• Other immunosuppressive drugs including, but not limited to, corticosteroids, cyclosporine, tacrolimus, rapamycin, mycophenolate mofetil, or azathioprine.
• Active significant infection
• Limited life expectancy because of disease other than diabetes
• Pregnancy

Where it is running

• Indiana University - Riley Hospital for Children — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.